Inari Medical [NARI] vs Abbott Laboratories [ABT] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Inari Medical Inc. wins in 2 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Inari Medical Inc. | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2,665.67 | 25.97 | Abbott Laboratories |
| Price-to-Book Ratio | 10.75 | 3.09 | Abbott Laboratories |
| Debt-to-Equity Ratio | 7.53 | 26.79 | Inari Medical Inc. |
| PEG Ratio | 571.21 | -1.41 | Inari Medical Inc. |
| EV/EBITDA | -176.14 | 13.74 | Abbott Laboratories |
| Profit Margin (TTM) | -13.68% | 13.90% | Abbott Laboratories |
| Operating Margin (TTM) | -4.34% | 16.50% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 16.50% | N/A |
| Return on Equity | -17.72% | 12.36% | Abbott Laboratories |
| Return on Assets (TTM) | -3.21% | 7.52% | Abbott Laboratories |
| Free Cash Flow (TTM) | N/A | $7.40B | N/A |
| Dividend Yield | N/A | 1.97% | N/A |
| 1-Year Return | N/A | -34.98% | N/A |
| Price-to-Sales Ratio (TTM) | 8.15 | 3.57 | Abbott Laboratories |
| Enterprise Value | $4.60B | $166.96B | Abbott Laboratories |
| EV/Revenue Ratio | 8.01 | 3.70 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 87.06% | N/A | N/A |
| Revenue per Share (TTM) | $10 | $26 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-1.35 | $3.57 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.03 | 0.78 | Abbott Laboratories |
| Short % of Float | N/A | 1.53% | N/A |
Inari Medical Inc. vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Inari Medical Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Abbott Laboratories | 0.56% | -2.02% | 4.97% | -19.35% | -30.98% | -28.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Inari Medical Inc. | N/A | N/A | N/A | N/A | N/A | N/A |
| Abbott Laboratories | -34.98% | -16.97% | -20.08% | 135.84% | 255.56% | 329.52% |
Performance & Financial Health Analysis: Inari Medical Inc. vs Abbott Laboratories
| Metric | NARI | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $4.68B | $160.70B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 1,052,478 | 13,495,583 |
| 90 Day Avg. Volume | 3,170,369 | 12,934,461 |
| Last Close | $79.97 | $88.67 |
| 52 Week Range | $36.73 - $79.99 | $81.97 - $139.06 |
| % from 52W High | -0.02% | -36.24% |
| All-Time High | $79.97 (Feb 19, 2025) | $142.60 (Dec 27, 2021) |
| % from All-Time High | 0.00% | -37.82% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.08% |
| Quarterly Earnings Growth | N/A | -0.19% |
| Financial Health | ||
| Profit Margin (TTM) | -0.14% | 0.14% |
| Operating Margin (TTM) | -0.04% | 0.17% |
| Return on Equity (TTM) | -0.18% | 0.12% |
| Debt to Equity (MRQ) | 7.53 | 26.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.44 | $30.02 |
| Cash per Share (MRQ) | $1.91 | $5.14 |
| Operating Cash Flow (TTM) | $14.18M | $10.80B |
| Levered Free Cash Flow (TTM) | $86.61M | $13.77B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.97% |
| Last 12-Month Dividend | N/A | $2.40 |
Valuation & Enterprise Metrics Analysis: Inari Medical Inc. vs Abbott Laboratories
| Metric | NARI (Mar 31, 2025) | ABT (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2,665.67 | 25.97 |
| Forward P/E | 571.21 | 15.29 |
| PEG Ratio | 571.21 | -1.41 |
| Price to Sales (TTM) | 8.15 | 3.57 |
| Price to Book (MRQ) | 10.75 | 3.09 |
| Market Capitalization | ||
| Market Capitalization | $4.68B | $160.70B |
| Enterprise Value | $4.60B | $166.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.01 | 3.70 |
| Enterprise to EBITDA | -176.14 | 13.74 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 0.78 |
| Book Value per Share (MRQ) | $7.44 | $30.02 |
Financial Statements Comparison: Inari Medical Inc. vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | NARI (2023) | ABT (2025) |
|---|---|---|
| Revenue/Sales | 493.63M | 44.33B |
| Cost of Goods Sold | 59.07M | 19.32B |
| COGS % of Revenue | 12.0% | 43.6% |
| Gross Profit | 434.56M | 25.01B |
| Gross Margin | 88.0% | 56.4% |
| Research & Development | 87.53M | 2.94B |
| Operating Income (EBIT) | -14.03M | 8.05B |
| Operating Margin | -2.8% | 18.2% |
| EBITDA | 15.18M | 12.03B |
| EBITDA Margin | 3.1% | 27.1% |
| Pre-Tax Income | 4.25M | 8.47B |
| Pre-Tax Income % of Revenue | 0.9% | 19.1% |
| Income Tax | 5.88M | 1.94B |
| Income Tax % of Revenue | 1.2% | 4.4% |
| Net Income (Profit) | -1.64M | 6.52B |
| Profit Margin | -0.3% | 14.7% |
Balance Sheet & Liquidity Metrics
| Metric | NARI (2023) | ABT (2025) |
|---|---|---|
| Cash & Equivalents | 38.60M | 8.52B |
| Total Current Assets | 235.56M | 26.00B |
| Total Current Assets % of Revenue | 47.7% | 58.6% |
| Total Current Liabilities | 76.34M | 16.50B |
| Total Current Liabilities % of Revenue | 15.5% | 37.2% |
| Long-Term Debt | 30.36M | 10.83B |
| Long-Term Debt % of Revenue | 6.1% | 24.4% |
| Total Shareholders Equity | 464.91M | 52.77B |
| Retained Earnings | -48.49M | 49.78B |
| Retained Earnings % of Revenue | -9.8% | 112.3% |
| Property, Plant & Equipment | 65.06M | 17.57B |
Cash Flow Statement Comparison
| Metric | NARI (2023) | ABT (2025) |
|---|---|---|
| Operating Cash Flow | N/A | 10.80B |
| Operating Cash Flow % of Revenue | 0.0% | 24.4% |
| Capital Expenditures | N/A | -2.17B |
| Free Cash Flow | N/A | 7.40B |
| FCF Margin | 0.0% | 16.7% |
| Debt Repayment | N/A | -1.50B |
| Common Stock Repurchase | N/A | -893.00M |
Short Interest & Institutional Ownership Analysis
| Metric | NARI | ABT |
|---|---|---|
| Shares Short | N/A | 23.83M |
| Short Ratio | N/A | 1.93 |
| Short % of Float | N/A | 1.53% |
| Shares Outstanding | 57.76M | 1.74B |
| Float Shares | 53.34M | 1.73B |
| % Held by Insiders | 9.00% | 0.54% |
| % Held by Institutions | 95.56% | 82.23% |
| % Held by Public | -4.56% | 17.23% |
Dividend Analysis & Yield Comparison: Inari Medical Inc. vs Abbott Laboratories
| Metric | NARI | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.40 |
| Last 12-Month Dividend Yield | N/A | 1.97% |
| 3-Year Avg Annual Dividend | N/A | $2.24 |
| 3-Year Avg Dividend Yield | N/A | 0.50% |
| 3-Year Total Dividends | N/A | $6.72 |
| Ex-Dividend Date | N/A | Jan 15, 2026 |